These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34398888)

  • 1. The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform.
    Maguire BJ; Dahal P; Rashan S; Ngu R; Boon A; Forsyth C; Strub-Wourgaft N; Chatelain E; Barreira F; Sosa-Estani S; Guérin PJ
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009697. PubMed ID: 34398888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.
    Villar JC; Perez JG; Cortes OL; Riarte A; Pepper M; Marin-Neto JA; Guyatt GH
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003463. PubMed ID: 24867876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina.
    Vizcaya D; Grossmann U; Kleinjung F; Zhang R; Suzart-Woischnik K; Seu S; Ramirez T; Colmegna L; Ledesma O
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009801. PubMed ID: 34606501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential new clinical therapies for Chagas disease.
    Bustamante JM; Tarleton RL
    Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for neglected infectious diseases: Chagas' disease.
    Machado FS; Tanowitz HB; Teixeira MM
    Br J Pharmacol; 2010 May; 160(2):258-9. PubMed ID: 20423339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
    Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
    Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
    Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
    Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.
    Jurado Medina L; Chassaing E; Ballering G; Gonzalez N; Marqué L; Liehl P; Pottel H; de Boer J; Chatelain E; Zrein M; Altcheh J
    Lancet Infect Dis; 2021 Aug; 21(8):1141-1150. PubMed ID: 33836157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapy and combination chemotherapy for Chagas disease treatment: a systematic review of clinical efficacy and safety based on randomized controlled trials.
    Santana Nogueira S; Cardoso Santos E; Oliveira Silva R; Vilela Gonçalves R; Lima GDA; Dias Novaes R
    Parasitology; 2022 Nov; 149(13):1679-1694. PubMed ID: 35957576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
    Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods.
    Muñoz C; Zulantay I; Apt W; Ortiz S; Schijman AG; Bisio M; Ferrada V; Herrera C; Martínez G; Solari A
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4518-23. PubMed ID: 23836179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.